| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 35 | 2024 | 3976 | 3.880 |
Why?
|
| Metformin | 13 | 2024 | 378 | 3.410 |
Why?
|
| Carcinoma, Squamous Cell | 40 | 2024 | 5437 | 3.060 |
Why?
|
| Papillomavirus Infections | 12 | 2024 | 980 | 2.440 |
Why?
|
| Esophageal Neoplasms | 29 | 2018 | 3168 | 1.740 |
Why?
|
| Radiation Tolerance | 13 | 2023 | 629 | 1.590 |
Why?
|
| Hypoglycemic Agents | 7 | 2021 | 586 | 1.530 |
Why?
|
| Chemoradiotherapy | 19 | 2021 | 1946 | 1.260 |
Why?
|
| Oropharyngeal Neoplasms | 12 | 2022 | 1105 | 1.130 |
Why?
|
| Adenocarcinoma | 20 | 2018 | 7789 | 1.060 |
Why?
|
| Homologous Recombination | 2 | 2021 | 185 | 0.900 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2024 | 3552 | 0.840 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 86 | 0.810 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 92 | 0.790 |
Why?
|
| Radiotherapy, Intensity-Modulated | 12 | 2023 | 2104 | 0.770 |
Why?
|
| Cell Line, Tumor | 32 | 2024 | 14551 | 0.770 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 126 | 0.760 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 411 | 0.710 |
Why?
|
| Neoplasm Recurrence, Local | 19 | 2019 | 10035 | 0.710 |
Why?
|
| Laryngeal Neoplasms | 6 | 2020 | 518 | 0.680 |
Why?
|
| Biomarkers, Tumor | 15 | 2023 | 10331 | 0.660 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.650 |
Why?
|
| Papillomaviridae | 7 | 2022 | 624 | 0.640 |
Why?
|
| Cisplatin | 8 | 2024 | 2432 | 0.640 |
Why?
|
| DNA Damage | 4 | 2022 | 1954 | 0.620 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2016 | 363 | 0.590 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2017 | 1678 | 0.590 |
Why?
|
| Humans | 120 | 2024 | 261506 | 0.570 |
Why?
|
| Nelfinavir | 1 | 2016 | 15 | 0.560 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 216 | 0.560 |
Why?
|
| Rectal Neoplasms | 2 | 2016 | 1202 | 0.550 |
Why?
|
| Malate Dehydrogenase | 1 | 2015 | 21 | 0.530 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 111 | 0.530 |
Why?
|
| Cellular Senescence | 2 | 2015 | 382 | 0.530 |
Why?
|
| Esophagectomy | 10 | 2017 | 911 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5319 | 0.520 |
Why?
|
| Glucose | 2 | 2023 | 1248 | 0.510 |
Why?
|
| Radiosurgery | 2 | 2024 | 1330 | 0.500 |
Why?
|
| Antineoplastic Agents | 13 | 2023 | 14289 | 0.500 |
Why?
|
| Signal Transduction | 10 | 2022 | 11965 | 0.500 |
Why?
|
| Salvage Therapy | 8 | 2019 | 2054 | 0.490 |
Why?
|
| Chemoradiotherapy, Adjuvant | 7 | 2017 | 565 | 0.490 |
Why?
|
| Furans | 1 | 2014 | 104 | 0.480 |
Why?
|
| Lung Neoplasms | 7 | 2024 | 11538 | 0.480 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2004 | 131 | 0.470 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 1823 | 0.470 |
Why?
|
| Middle Aged | 62 | 2021 | 86204 | 0.470 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2021 | 3821 | 0.470 |
Why?
|
| Neoplasm Staging | 17 | 2021 | 13658 | 0.460 |
Why?
|
| MicroRNAs | 2 | 2018 | 2947 | 0.450 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 661 | 0.440 |
Why?
|
| Aged | 55 | 2021 | 70117 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2017 | 2488 | 0.440 |
Why?
|
| Male | 70 | 2021 | 123000 | 0.440 |
Why?
|
| Proteomics | 3 | 2017 | 1380 | 0.440 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 347 | 0.440 |
Why?
|
| Mouth Neoplasms | 4 | 2020 | 713 | 0.430 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 5 | 2018 | 259 | 0.420 |
Why?
|
| Proteome | 1 | 2016 | 561 | 0.420 |
Why?
|
| Esophagogastric Junction | 4 | 2017 | 543 | 0.410 |
Why?
|
| Retrospective Studies | 40 | 2024 | 37905 | 0.400 |
Why?
|
| Protein Conformation | 1 | 2014 | 1258 | 0.390 |
Why?
|
| Diabetes Complications | 1 | 2012 | 305 | 0.370 |
Why?
|
| Female | 63 | 2021 | 141928 | 0.370 |
Why?
|
| Diabetes Mellitus | 3 | 2015 | 1054 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2020 | 8873 | 0.360 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2022 | 476 | 0.360 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2011 | 137 | 0.350 |
Why?
|
| Treatment Outcome | 24 | 2019 | 32848 | 0.340 |
Why?
|
| Radiometry | 3 | 2017 | 980 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 2027 | 0.340 |
Why?
|
| Combined Modality Therapy | 17 | 2020 | 8865 | 0.330 |
Why?
|
| Eye Neoplasms | 1 | 2011 | 247 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2018 | 3251 | 0.320 |
Why?
|
| Aged, 80 and over | 27 | 2020 | 29902 | 0.320 |
Why?
|
| Thyroid Neoplasms | 5 | 2018 | 1866 | 0.320 |
Why?
|
| Disease-Free Survival | 17 | 2020 | 10001 | 0.310 |
Why?
|
| Positron-Emission Tomography | 6 | 2020 | 2173 | 0.290 |
Why?
|
| Neoplasm Metastasis | 7 | 2018 | 5112 | 0.290 |
Why?
|
| Adult | 43 | 2019 | 77950 | 0.280 |
Why?
|
| Liver Neoplasms | 3 | 2014 | 4557 | 0.280 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2017 | 726 | 0.280 |
Why?
|
| Mastectomy | 1 | 2013 | 1534 | 0.280 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2295 | 0.270 |
Why?
|
| Transcription Factors | 6 | 2018 | 5270 | 0.270 |
Why?
|
| Induction Chemotherapy | 3 | 2018 | 669 | 0.270 |
Why?
|
| Cetuximab | 3 | 2017 | 472 | 0.270 |
Why?
|
| Reactive Oxygen Species | 4 | 2015 | 987 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 15862 | 0.260 |
Why?
|
| Apoptosis | 7 | 2021 | 7591 | 0.260 |
Why?
|
| Aging | 2 | 2011 | 1582 | 0.250 |
Why?
|
| Prognosis | 18 | 2022 | 21713 | 0.250 |
Why?
|
| Mice, Nude | 8 | 2021 | 4307 | 0.250 |
Why?
|
| Lactic Acid | 2 | 2017 | 305 | 0.250 |
Why?
|
| Radiotherapy Dosage | 6 | 2023 | 3842 | 0.250 |
Why?
|
| Survival Rate | 13 | 2020 | 12221 | 0.240 |
Why?
|
| Arsenites | 1 | 2004 | 18 | 0.240 |
Why?
|
| Survival Analysis | 11 | 2020 | 9180 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 7 | 2018 | 4975 | 0.240 |
Why?
|
| Teratogens | 1 | 2004 | 81 | 0.230 |
Why?
|
| Mutation | 9 | 2022 | 15179 | 0.230 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 85 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2018 | 1439 | 0.220 |
Why?
|
| Neoplasms | 6 | 2023 | 15193 | 0.220 |
Why?
|
| Lymph Nodes | 3 | 2020 | 2967 | 0.220 |
Why?
|
| Pyrimidinones | 3 | 2020 | 314 | 0.220 |
Why?
|
| Fluorouracil | 6 | 2017 | 1944 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1362 | 0.210 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1833 | 0.210 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 40 | 0.210 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2018 | 1226 | 0.210 |
Why?
|
| Glottis | 2 | 2019 | 67 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 7551 | 0.210 |
Why?
|
| Prospective Studies | 11 | 2024 | 12873 | 0.200 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 14889 | 0.200 |
Why?
|
| Animals | 20 | 2021 | 59536 | 0.200 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2020 | 799 | 0.200 |
Why?
|
| Pyrazoles | 3 | 2020 | 1471 | 0.190 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.190 |
Why?
|
| Histones | 3 | 2017 | 1466 | 0.190 |
Why?
|
| Caspase 8 | 1 | 2020 | 145 | 0.190 |
Why?
|
| Gene Expression | 4 | 2018 | 3570 | 0.190 |
Why?
|
| Mice | 13 | 2021 | 34495 | 0.190 |
Why?
|
| Acetylation | 1 | 2021 | 508 | 0.180 |
Why?
|
| Radiation, Ionizing | 3 | 2015 | 187 | 0.180 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1070 | 0.180 |
Why?
|
| Protein Domains | 1 | 2021 | 314 | 0.180 |
Why?
|
| Ubiquitin | 1 | 2022 | 344 | 0.180 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 7222 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 694 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2019 | 58 | 0.170 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2019 | 60 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 3343 | 0.170 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 60 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2019 | 39 | 0.170 |
Why?
|
| Single-Blind Method | 1 | 2020 | 409 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2024 | 406 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 1443 | 0.170 |
Why?
|
| Cell Survival | 3 | 2014 | 3045 | 0.170 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 253 | 0.160 |
Why?
|
| Young Adult | 13 | 2019 | 21445 | 0.160 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 493 | 0.160 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 4298 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2018 | 833 | 0.160 |
Why?
|
| Margins of Excision | 1 | 2020 | 285 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2017 | 6207 | 0.160 |
Why?
|
| Rectal Diseases | 1 | 2018 | 55 | 0.160 |
Why?
|
| Indazoles | 1 | 2020 | 297 | 0.160 |
Why?
|
| Urination Disorders | 1 | 2018 | 61 | 0.160 |
Why?
|
| Radiation Oncology | 1 | 2023 | 529 | 0.160 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 1162 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 129 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 1533 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2023 | 5178 | 0.160 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.160 |
Why?
|
| Treatment Failure | 4 | 2016 | 1391 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 199 | 0.150 |
Why?
|
| Radiation Injuries | 4 | 2018 | 1411 | 0.150 |
Why?
|
| Veterans | 3 | 2019 | 1641 | 0.150 |
Why?
|
| Deglutition Disorders | 2 | 2019 | 447 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 322 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 190 | 0.150 |
Why?
|
| Linear Models | 3 | 2019 | 1085 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2020 | 191 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2020 | 324 | 0.150 |
Why?
|
| Laryngectomy | 2 | 2016 | 242 | 0.150 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 111 | 0.150 |
Why?
|
| Genomics | 3 | 2019 | 2738 | 0.150 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2023 | 2370 | 0.140 |
Why?
|
| Mitochondria | 4 | 2020 | 1282 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 854 | 0.140 |
Why?
|
| Survivors | 2 | 2019 | 1031 | 0.140 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 4844 | 0.140 |
Why?
|
| Skull Base | 1 | 2017 | 199 | 0.140 |
Why?
|
| Cell Proliferation | 8 | 2017 | 7226 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.140 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 4988 | 0.140 |
Why?
|
| Glycolysis | 3 | 2014 | 519 | 0.140 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 316 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2019 | 6869 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2014 | 886 | 0.140 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2018 | 192 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2016 | 174 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2014 | 1824 | 0.130 |
Why?
|
| Proton Therapy | 3 | 2017 | 1577 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 479 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1077 | 0.130 |
Why?
|
| Serous Membrane | 1 | 2015 | 9 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2019 | 9244 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 627 | 0.130 |
Why?
|
| Medical Oncology | 2 | 2023 | 1423 | 0.130 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2015 | 119 | 0.130 |
Why?
|
| Tumor Burden | 3 | 2017 | 1987 | 0.130 |
Why?
|
| Deoxyglucose | 2 | 2012 | 115 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1648 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2017 | 575 | 0.130 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2014 | 87 | 0.130 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1152 | 0.130 |
Why?
|
| Radiation | 1 | 2014 | 20 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 295 | 0.120 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 110 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2015 | 550 | 0.120 |
Why?
|
| Piperidines | 1 | 2020 | 1035 | 0.120 |
Why?
|
| beta-Galactosidase | 1 | 2014 | 211 | 0.120 |
Why?
|
| Prostatic Neoplasms | 4 | 2018 | 5767 | 0.120 |
Why?
|
| Cancer Survivors | 2 | 2020 | 650 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2007 | 376 | 0.120 |
Why?
|
| Aniline Compounds | 1 | 2015 | 177 | 0.120 |
Why?
|
| Risk Factors | 7 | 2019 | 17523 | 0.120 |
Why?
|
| Mucous Membrane | 1 | 2015 | 271 | 0.120 |
Why?
|
| Telemedicine | 1 | 2020 | 471 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 2278 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 275 | 0.120 |
Why?
|
| Blotting, Western | 4 | 2015 | 3536 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 528 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 607 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2014 | 240 | 0.120 |
Why?
|
| Smoking | 4 | 2015 | 2440 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 91 | 0.120 |
Why?
|
| Skull Base Neoplasms | 1 | 2017 | 314 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2022 | 2022 | 0.120 |
Why?
|
| Cancer Care Facilities | 3 | 2017 | 884 | 0.120 |
Why?
|
| Bilirubin | 1 | 2014 | 221 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 1265 | 0.110 |
Why?
|
| Body Composition | 1 | 2016 | 595 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1546 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 1062 | 0.110 |
Why?
|
| Tongue Neoplasms | 1 | 2015 | 246 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2016 | 829 | 0.110 |
Why?
|
| Carbon Isotopes | 1 | 2014 | 333 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 301 | 0.110 |
Why?
|
| Texas | 5 | 2020 | 6311 | 0.110 |
Why?
|
| Pyruvic Acid | 1 | 2014 | 133 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 333 | 0.110 |
Why?
|
| Vaginal Neoplasms | 1 | 2013 | 152 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 992 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2013 | 220 | 0.100 |
Why?
|
| Ions | 1 | 2011 | 53 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2017 | 1620 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 161 | 0.100 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 236 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2017 | 6150 | 0.100 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2005 | 268 | 0.100 |
Why?
|
| Cell Death | 1 | 2014 | 671 | 0.100 |
Why?
|
| Isoenzymes | 1 | 2013 | 614 | 0.100 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 413 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 1283 | 0.100 |
Why?
|
| Carbon | 1 | 2011 | 149 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 7702 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 5395 | 0.090 |
Why?
|
| United States | 4 | 2019 | 15433 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1331 | 0.090 |
Why?
|
| Incidence | 3 | 2019 | 5673 | 0.090 |
Why?
|
| Esophagus | 1 | 2013 | 553 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2015 | 2074 | 0.090 |
Why?
|
| Sirolimus | 2 | 2004 | 814 | 0.090 |
Why?
|
| Pyrimidines | 3 | 2016 | 3518 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.090 |
Why?
|
| Organs at Risk | 2 | 2023 | 514 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4638 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1301 | 0.090 |
Why?
|
| Anus Neoplasms | 1 | 2013 | 411 | 0.090 |
Why?
|
| Pharynx | 2 | 2020 | 153 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 15694 | 0.080 |
Why?
|
| Quality of Life | 2 | 2020 | 4532 | 0.080 |
Why?
|
| Particle Accelerators | 1 | 2011 | 352 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 1270 | 0.080 |
Why?
|
| Survivorship | 2 | 2020 | 109 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2014 | 1764 | 0.080 |
Why?
|
| Chromones | 2 | 2006 | 120 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 992 | 0.080 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2007 | 15 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2006 | 4804 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1756 | 0.080 |
Why?
|
| Drug Synergism | 3 | 2015 | 1313 | 0.080 |
Why?
|
| Taxoids | 3 | 2016 | 967 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2020 | 745 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4078 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 4757 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 5159 | 0.070 |
Why?
|
| Morpholines | 2 | 2006 | 289 | 0.070 |
Why?
|
| Visual Acuity | 1 | 2011 | 873 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2015 | 1823 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 672 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 2045 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2015 | 3981 | 0.070 |
Why?
|
| Leptin | 2 | 2006 | 295 | 0.070 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2005 | 8 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 272 | 0.070 |
Why?
|
| Caspases | 2 | 2020 | 661 | 0.070 |
Why?
|
| Reflex, Startle | 1 | 2005 | 65 | 0.070 |
Why?
|
| Neck Dissection | 2 | 2019 | 290 | 0.070 |
Why?
|
| Platinum Compounds | 2 | 2017 | 131 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 5539 | 0.060 |
Why?
|
| Receptors, Cell Surface | 2 | 2006 | 862 | 0.060 |
Why?
|
| Remission Induction | 3 | 2017 | 3569 | 0.060 |
Why?
|
| Genes, p53 | 2 | 2022 | 1090 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2004 | 55 | 0.060 |
Why?
|
| Prevalence | 1 | 2012 | 3260 | 0.060 |
Why?
|
| Mitochondrial Proteins | 2 | 2020 | 369 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 2 | 2015 | 183 | 0.060 |
Why?
|
| Carcinoma | 1 | 2015 | 2578 | 0.060 |
Why?
|
| Nomograms | 2 | 2016 | 313 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 4654 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2016 | 702 | 0.060 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 104 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1516 | 0.050 |
Why?
|
| Hospitals, Veterans | 2 | 2015 | 397 | 0.050 |
Why?
|
| Fear | 1 | 2003 | 254 | 0.050 |
Why?
|
| Heterografts | 2 | 2014 | 733 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 507 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 249 | 0.050 |
Why?
|
| Biomimetics | 1 | 2020 | 33 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 2944 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2016 | 1014 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4849 | 0.050 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 25 | 0.050 |
Why?
|
| Pennsylvania | 1 | 2020 | 64 | 0.050 |
Why?
|
| Dipeptides | 1 | 2020 | 91 | 0.050 |
Why?
|
| Radiography | 2 | 2016 | 1904 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 2231 | 0.050 |
Why?
|
| Protein Binding | 2 | 2018 | 3438 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2003 | 492 | 0.040 |
Why?
|
| Biomarkers | 2 | 2023 | 5047 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6009 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2004 | 874 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 5061 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4314 | 0.040 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 1258 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 311 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 249 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2019 | 348 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 397 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2019 | 756 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 158 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 276 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 205 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 621 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2019 | 240 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 180 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3890 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3033 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 550 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 277 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 254 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 2054 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2018 | 798 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 292 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2017 | 224 | 0.030 |
Why?
|
| G2 Phase | 1 | 2016 | 206 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 463 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 700 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2020 | 621 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 497 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 2 | 2006 | 24 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 176 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2015 | 76 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 15 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 1643 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7548 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 2 | 2006 | 60 | 0.030 |
Why?
|
| Receptors, Leptin | 2 | 2006 | 62 | 0.030 |
Why?
|
| Capecitabine | 1 | 2016 | 388 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1009 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 592 | 0.030 |
Why?
|
| Mucositis | 1 | 2015 | 148 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 216 | 0.030 |
Why?
|
| Stomatitis | 1 | 2016 | 183 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 289 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 436 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 388 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 424 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 1489 | 0.030 |
Why?
|
| SOX9 Transcription Factor | 1 | 2015 | 170 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 54 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Fluoresceins | 1 | 2014 | 73 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 323 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 384 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1026 | 0.030 |
Why?
|
| Repressor Proteins | 2 | 2016 | 1664 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 222 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 925 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 739 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 663 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 256 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1742 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 1290 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 2084 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 4938 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 430 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 699 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 823 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 31252 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 285 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2016 | 938 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2013 | 128 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 2218 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2006 | 639 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 344 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.030 |
Why?
|
| Cell Separation | 1 | 2014 | 612 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 717 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 1082 | 0.030 |
Why?
|
| Weight Loss | 1 | 2016 | 627 | 0.030 |
Why?
|
| Rectum | 1 | 2014 | 467 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 584 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 551 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 39 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2307 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 968 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 624 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 324 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1440 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2014 | 575 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 478 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1519 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 902 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1084 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 401 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 4143 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 2063 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2864 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 1382 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1509 | 0.020 |
Why?
|
| Prostate | 1 | 2014 | 1088 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 2203 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 2170 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 2216 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1299 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 4320 | 0.020 |
Why?
|
| Butadienes | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 2466 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 12926 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1859 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 445 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2005 | 54 | 0.020 |
Why?
|
| Tritium | 1 | 2005 | 200 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 6086 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 300 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2005 | 118 | 0.020 |
Why?
|
| Disease Progression | 1 | 2016 | 6682 | 0.020 |
Why?
|
| Corticosterone | 1 | 2003 | 119 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2003 | 156 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2330 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 842 | 0.010 |
Why?
|
| Nitriles | 1 | 2006 | 906 | 0.010 |
Why?
|
| Pregnancy | 2 | 2005 | 7573 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2003 | 482 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 2489 | 0.010 |
Why?
|
| Hippocampus | 1 | 2005 | 915 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2003 | 1338 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 1879 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 1244 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 526 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 3472 | 0.010 |
Why?
|
| Piperazines | 1 | 2005 | 2101 | 0.010 |
Why?
|